In accordance with A1M Pharma’s articles of association, the Board of Directors shall consist of a minimum of three and a maximum of eight board members, with a maximum of three deputy board members. The company’s Board of Directors currently consists of six board members and one deputy board member. The registered office is in Lund Municipality. The board members are elected for the period until the end of the 2018 Annual General Meeting. The holdings are adjusted in accordance with known changes following the Preferential Rights Issue that closed on 7 April 2017, as well as the consolidation of shares (1:20).

Name Position Born Appointed Shares* Warrants
2015/2018*
Warrants
2017**
Dependent
in relation
to company
Dependent
in relation
to major
shareholders
Martin Austin Chairman of the Board 1952 April 2016 4 569 75 000 22 843 Yes No
Anders Ermén Board member 1963 November 2012 325 - - Yes Yes
Christina Glad Board member 1952 November 2012 3 141 75 000 - No No
Stefan Hansson Board member 1965 Juni 2008 99 983 25 000 - No No
Christina Östberg Lloyd Board member 1961 Oktober 2014 - - - No< No
Bo Åkerström Board member 1952 Juni 2008 130 158 25 000 - No No
Magnus Gram Deputy board member 1980 Juni 2012 33 792 30 000 - No No

* 12 warrants 2015/2018 providing entitlement to subscription to a new share at a price of SEK 115.25.
** 20 warrants 2017 providing entitlement to subscription to a new share at a price of SEK 15.00.


The Board of Directors of A1M Pharma AB

Martin Austin
Martin Austin
Chairman of the Board

Chairman of the Board since April 2016.
Born: 1952
Education and experience: Martin Austin is an international expert on finance, strategy and business development in sectors including pharmaceuticals, biotechnology and medical technology. Martin has over 35 years’ experience in the pharmaceutical industry.
Other assignments: Martin Austin is chairman of the board at Preelumina Diagnostics AB and Zestagen SA, a board member at Algipharma SA, Devirex AG and RSA AG, as well as a partner in MarraM Sarl. He is also an adviser to a number of boards and investment funds, as well as course director for the Centre for Executive Leadership for the Pharmaceutical Industry in Brussels. Martin is the owner and managing director of TransformRx GmbH. In addition to his board role, Martin is also a consultant for the Company.
Previous assignments in the last five years: Martin Austin has previously served as business development manager for the pharmaceutical division at Roche and was a member of the management team at Paul Capital Partners. He has been a director of several start-up companies and is also an adviser to a number of boards and investment funds.
Holding: 4,569 shares, 75,000 warrants 2015/2018, and 22,843 warrants 2017.
 
Anders Ermén
Anders Ermén
Board member

Board member since November 2012.
Born: 1963
Education and experience: Anders Ermén is an economist and has more than 20 years’ experience from the music and media industry, both nationally and internationally. He also has extensive experience of taxation issues and contract negotiation.
Other assignments: Anders Ermén has run his own accounting, business development and management firm since 1996. Anders is chairman of the board at Enorama Pharma AB and a board member at Preelumina Diagnostics AB, Baulos Capital Belgium SA, and Ermén Produktion & Redovisning AB. He also owns Ermén Produktion & Redovisning AB and is a proprietor of Ermén Konsult Enskild Firma. Anders Ermén has represented the principal owner Baulos Capital Belgium SA on A1M Pharma’s board since 2012. In addition to his board role, Anders is also a consultant for the Company.
Previous assignments in the last five years: Former partner in Ermén & Sand HB.
Holding: 325 shares privately, through companies and related parties.
 
Christina Glad
Cristina Glad
Board member

Board member since November 2012.
Born: 1952
Education and experience: Cristina Glad has a PhD in Biochemistry and an Executive MBA. Cristina has more than 25 years’ experience in research and business development within biotechnology and pharmaceutical development, including antibodies for diagnostic and therapeutic use, development of production processes for antibody drugs, establishing contract production operations and development of antibody drugs, as well as experience of research and development projects with biotechnology and pharmaceutical companies, and in-licensing and out-licensing of projects. In her previous role as a CEO and a deputy CEO, Cristina participated in the development of BioInvent International AB from a technology platform company to a company with a number of drug candidates in its product portfolio. She has been a consultant with her own company since December 2013. Cristina is a member of the Royal Swedish Academy of Engineering Sciences (IVA).
Other assignments: Cristina Glad is a board member at Ideonfonden AB, Medeon Aktiebolag, Preelumina Diagnostics AB, and RhoVac AB, and since December 2012 has owned and run C Glad Consulting AB, where she is the sole board member. In addition to her board role, Cristina is also a consultant for the Company.
Previous assignments in the last five years: Cristina Glad has been CEO and deputy CEO of BioInvent International AB and has also been a board member at BioInvent Finans AB.
Holding: 3,141 shares and 75,000 warrants 2015/2018.
 
Stefan Hansson
Stefan Hansson
Board member

Board member since June 2008.
Born: 1965
Education and experience: Stefan Hansson is a senior consultant and professor in obstetrics and gynaecology. Stefan Hansson is a co-founder of A1M Pharma. Stefan is also an inventor and a co-founder of Preelumina Diagnostics AB, and is the senior manager for clinical research and development at the Company. Stefan works as a professor and senior consultant in obstetrics and gynaecology at Lund University and at the Women’s Clinic at Skåne University Hospital in southern Sweden. He has published 80 scientific articles and been a key figure in identifying the role played by free fetal hemoglobin in pre-eclampsia. Stefan Hansson is an inventor with five patents/patent applications to his name. Stefan is currently vice dean with specific responsibility for third-cycle programmes at the Faculty of Medicine at Lund University. Since 1999 Stefan’s research has focused on pre-eclampsia.
Other assignments: Stefan Hansson is vice dean with specific responsibility for third-cycle programmes at the Faculty of Medicine at Lund University, and he also works as a professor and senior consultant in obstetrics and gynaecology at Lund University, and at the Women’s Clinic at Skåne University Hospital in southern Sweden. Stefan Hansson is a board member at Preelumina Diagnostics AB and S.R. Hansson Medicinsk Konsult AB, and a deputy board member at BEWETE AB. Stefan is also a co-founder and the CEO of Hälsomedicinskt Center Barnmorskemottagning AB, where he is a board member and shareholder (18 per cent of the shares). Stefan Hansson is the founder, CEO and owner of S.R. Hansson Medicinsk Konsult AB.
Previous assignments in the last five years: No completed previous assignments or partnerships over five per cent in the last five years.
Holding: 99,983 shares together with related parties. Stefan Hansson also holds 25,000 warrants 2015/2018.
 
Christina Lloyd
Christina Östberg Lloyd
Board member

Board member since October 2014.
Born: 1961
Education and experience: Christina Lloyd is a doctor and a specialist in gynaecology and obstetrics, and has also studied Medical Business Strategy (MBS) at the Scandinavian International Management Institute (SIMI) in Copenhagen. Christina Lloyd has been Clinical Medical Regulatory Director at Novo Nordisk Scandinavia AB since 2009, with responsibility for regulatory affairs, safety and quality management. Clinical research there represents all aspects of the company’s continuous clinical pharmaceutical development programme, and within the medical affairs field Christina is responsible for, among other matters, long-term scientific dialogue with external partners and preparing the market for forthcoming launches.
Other assignments: Christina Lloyd is Clinical Medical Regulatory Director at Novo Nordisk Scandinavia AB, with responsibility for regulatory affairs, safety and quality management. Christina also has ongoing board assignments at, among others, Strategiska Innovationsområde för Folksjukdomar (SWElife), a governing body for the SIO (strategic innovation area) programme in partnership with VINNOVA. Christina is a board member at D&C Design & Care AB.
Previous assignments in the last five years: At the start of the 2000s, Christina Lloyd was combining clinical work at the Women’s Clinic at Lund University with work within the pharmaceutical industry, but later moved on to focus solely on the latter as Nordic Medical Director at Ferring Pharmaceuticals. Christina Lloyd has no partnerships over five per cent and has had no partnerships over five per cent in the last five years. Christina Lloyd has no completed assignments.
Holding:
 
Bo Åkerstrom
Bo Åkerström
Board member

Board member since June 2008.
Born: 1952
Education and experience: Bo Åkerström is a professor of medical chemistry and the author of approx. 150 scientific articles, and has had a key role in the discovery of the A1M molecule and its functions in the body. Bo Åkerström is a world leader in this field of research and has been the inspiration behind a number of the A1M protein’s medical applications. Bo is an inventor, holding eight patents/patent applications within A1M Pharma’s medical field, and has been responsible for three inventions that resulted in patents and biotechnology products (protein G and protein L, General Electric Healthcare). Other assignments: Bo Åkerström is a co-founder of A1M Pharma and is responsible for the Company’s preclinical research. Bo is a board member at Preelumina Diagnostics AB. He is a partner (50 per cent) in Rim & Reson Musikproduktion HB and the owner of Åkerström Produktion.
Previous assignments in the last five years: Bo Åkerström has previously been a board member at BRF Prennebo.
Holding: 130,158 shares together with related parties. Bo Åkerström also holds 25,000 warrants 2015/2018.
 
Magnus Gram
Magnus Gram
Deputy board member

Deputy board member since June 2012.
Born: 1980
Education and experience: Magnus Gram is a doctor of medical science, researcher and project manager. Magnus Gram is one of the inventors and founders of A1M Pharma. Magnus has also provided the inspiration for several of the A1M protein’s medical applications and is responsible for a number of patents/patent applications within the Company’s medical field. Other assignments: Magnus Gram has been a deputy board member at the subsidiary Preelumina Diagnostics AB since 2012.
Previous assignments in the last five years: Magnus Gram has no partnerships over five per cent and has had no partnerships over five per cent in the last five years. Magnus Gram has no completed assignments.
Holding: 33,792 shares. Magnus Gram also holds 30,000 warrants 2015/2018.
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Medlem av Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M